CYBIN INC. - and – ODYSSEY TRUST COMPANY WARRANT INDENTURE Providing for the Issue of up to 8,107,720 Common Share Purchase Warrants February 4, 2021Cybin Inc. • July 26th, 2021 • Ontario
ODYSSEY TRUST COMPANY, a trust company incorporated under the laws of Alberta and authorized to carry on business in the provinces of Alberta and British Columbia (the “Warrant Agent”)
UNDERWRITING AGREEMENTUnderwriting Agreement • July 26th, 2021 • Cybin Inc. • Ontario
The Warrants shall be duly and validly created and issued pursuant to, and governed by, a warrant indenture (the "Warrant Indenture") in a form acceptable to the Lead Underwriter (acting reasonably) to be dated as of the Closing Date between the Corporation and the Transfer Agent (as defined below), in its capacity as warrant agent. The description of the Warrants herein is a summary only and is subject to the specific attributes and detailed provisions of the Warrants to be set forth in the Warrant Indenture. In case of any inconsistency between the description of the Warrants in this Agreement (as defined below) and the terms of the Warrants set forth in the Warrant Indenture, the provisions of the Warrant Indenture will govern.
PURCHASE AGREEMENTPurchase Agreement • May 31st, 2023 • Cybin Inc. • Pharmaceutical preparations • New York
THIS PURCHASE AGREEMENT (the “Agreement”), dated as of May 30, 2023 (the “Execution Date”), is entered into by and between CYBIN INC., a corporation incorporated and existing under the laws of the Province of Ontario (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
SHAREHOLDER RIGHTS PLAN AGREEMENT DATED AS OF AUGUST 16, 2021 BETWEEN CYBIN INC. AND ODYSSEY TRUST COMPANY AS RIGHTS AGENTShareholder Rights Plan Agreement • August 17th, 2021 • Cybin Inc. • Pharmaceutical preparations • Ontario
the Rights represented by this Rights Certificate, together with all right, title and interest therein, and does hereby irrevocably constitute and appoint , as attorney, to transfer the within Rights on the books of the Corporation, with full power of substitution.
Cybin Inc. Shares of Common Stock EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • August 24th, 2023 • Cybin Inc. • Pharmaceutical preparations • New York
Cybin Inc., a company continued under the Business Corporations Act (Ontario) ("Cybin" or the "Company"), confirms its agreement (this "Agreement") with Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald & Co. (each individually an "Agent" and, collectively, the "Agents") to issue and sell common shares of the Company ("Shares") upon and subject to the terms and conditions contained herein. Capitalized terms used herein have the meanings given to them in Section 23 hereof.
ESCROW AGREEMENTEscrow Agreement • July 26th, 2021 • Cybin Inc. • Ontario
This Agreement is being entered into by the Parties under National Policy 46-201 Escrow for Initial Public Offerings (the Policy) in connection with the application by the Issuer, an established issuer, for listing of the common shares of the Issuer on the NEO Exchange.
SUPPORT AGREEMENTSupport Agreement • July 26th, 2021 • Cybin Inc. • Ontario
This SUPPORT AGREEMENT is made as of December 14, 2020 (this “Agreement”), among Cybin Inc. (the “Parent”), an Ontario corporation, Cybin US Holdings Inc. (the “Acquiror”), a Nevada corporation, and each of those persons listed in exhibit “A” (each a “Shareholder” and together the “Shareholders”);
UNDERWRITING AGREEMENTUnderwriting Agreement • November 13th, 2023 • Cybin Inc. • Pharmaceutical preparations • New York
Each Unit will consist of one Common Share (as hereinafter defined) (each, a "Unit Share" and collectively, the "Unit Shares") and one Common Share purchase warrant (each, a "Warrant" and collectively, the "Warrants"). Each whole Warrant will entitle the holder thereof to purchase one additional Common Share (each, a "Warrant Share" and collectively, the "Warrant Shares"), subject to adjustment in certain circumstances, at a price of $0.51 per Warrant Share at any time prior to the Expiry Date (as hereinafter defined).
ARRANGEMENT AGREEMENT BETWEEN CYBIN INC. – AND – SMALL PHARMA INC. August 28, 2023Arrangement Agreement • September 12th, 2023 • Cybin Inc. • Pharmaceutical preparations • Ontario
References in this Schedule D to “this Agreement” mean the arrangement agreement of which this Schedule D forms a part, and references in this Schedule D to a Section “of the Arrangement Agreement” mean a Section of the main body of this Agreement.
MEMORANDUM OF UNDERSTANDING TO UNDERTAKE CLINICAL RESEARCH IN THE PROPERTIES OF MUSHROOM (Psilocybin) AND APPLICATIONS IN CLINICAL TRIALS BETWEEN THE UNIVERSITY OF THE WEST INDIES through THE CARIBBEAN INSTITUTE FOR HEALTH RESEARCH - TROPICAL...Cybin Inc. • July 26th, 2021
This Memorandum of Understanding for the provision of technical support in mushroom research and development (hereinafter referred to as “MOU”) is made and entered into on the 16th day of July, 2020 between THE UNIVERSITY OF THE WEST INDIES, a regional academic institution with Regional Headquarters located at Hermitage Road, Mona, Kingston 7, Jamaica W.I. (hereinafter referred to as “The UWI”) through its TROPICAL METABOLISM RESEARCH UNIT of THE CARIBBEAN INSTITUTE FOR HEALTH RESEARCH, (hereinafter referred to as “CAIHR-TMRU”) and CYBIN Corporation an Ontario, Canada based private firm located at 5600-100 King Street West, Toronto, ON M5X 1C9, Canada (hereinafter referred to as “CYBIN”) (collectively referred to as the “Parties”).
CONTRIBUTION AGREEMENT BY AND AMONG CYBIN INC. CYBIN CORP. CYBIN US HOLDINGS INC. ADELIA THERAPEUTICS INC. THE SHAREHOLDERS OF ADELIA THERAPEUTICS INC. AND ALEX NIVOROZHKIN, AS THE CONTRIBUTORS REPRESENTATIVE DATED AS OF DECEMBER 4, 2020Contribution Agreement • July 26th, 2021 • Cybin Inc. • Delaware
THIS CONTRIBUTION AGREEMENT (this “Agreement”), dated as of December 4, 2020 is entered into by and among (i) Cybin US Holdings Inc., a Nevada corporation (“Acquiror”), (ii) Cybin Corp., an Ontario corporation (“Acquiror Intermediate Holdco”), (iii) Cybin Inc., an Ontario corporation (“Acquiror Topco”), (iv) Alex Nivorozhkin, Brett Greene, Michael Palfreyman, Clinton Canal, Alexander Belser, Nova Capital International LLC, Transliminal LLC and Josh Hartsel (each, a “Contributor” and collectively the “Contributors”), (v) Adelia Therapeutics Inc., a Delaware corporation (the “Company”), and (vi) Alex Nivorozhkin, in his capacity as the Contributors Representative.
CYBIN INC. as Issuer and [ ] as U.S. Trustee and [ ] as Canadian Trustee Indenture Dated as of [ ]Cybin • December 29th, 2023 • Cybin Inc. • Pharmaceutical preparations • Ontario
This Indenture is subject to the provisions of Trust Indenture Legislation that are required to be part of this Indenture and shall, to the extent applicable, be governed by such provisions.
AMALGAMATION AGREEMENTAmalgamation Agreement • July 26th, 2021 • Cybin Inc. • Ontario
UNDERWRITING AGREEMENTUnderwriting Agreement • August 2nd, 2023 • Cybin Inc. • Pharmaceutical preparations • New York
AGENCY AGREEMENTAgency Agreement • July 26th, 2021 • Cybin Inc. • Ontario
The Subscription Receipts will be created pursuant to a subscription receipt agreement (the "Subscription Receipt Agreement") among the Corporation, the Co-Lead Agents and Odyssey Trust Company, as subscription receipt agent (the "Subscription Receipt Agent"), to be dated as of the Closing Date (as defined herein). Each Subscription Receipt will, upon the satisfaction, or waiver in whole or in part by the Co-Lead Agents, on behalf of the Agents, in their sole discretion, of the Escrow Release Conditions (as defined herein), and without payment of additional consideration or further action on the part of the holders of the Subscription Receipts, be automatically converted into one common share in the capital of the Corporation (each, a "Common Share" and collectively, the "Common Shares"). Immediately following the issuance of the Common Shares upon conversion of Subscription Receipts, each Common Share will be automatically exchanged for a common share of the Resulting Issuer (as defin
FEASIBILITY STUDY AGREEMENTFeasibility Study Agreement • July 26th, 2021 • Cybin Inc. • Ontario
CYBIN CORP., a corporation with offices at 100 King Street West, Suite 5600, Toronto, Ontario M5X 1C9, Canada, together with its Affiliates (as hereinafter defined), herein represented by Paul Glavine, its CEO (“CYBIN”)
AGENCY AGREEMENTAgency Agreement • March 21st, 2024 • Cybin Inc. • Pharmaceutical preparations
Bloom Burton Securities Inc. (the "Lead Agent") and Haywood Securities Inc. (together with the Lead Agent, the "Agents") understand that Cybin Inc. (the "Corporation") proposes to issue and/or sell, as applicable, on a "commercially reasonable efforts" private placement basis, without underwriter liability, common shares (the "Offered Shares") in the capital of the Corporation at a price of $0.43 per Offered Share for gross proceeds of up to $150 million, or such other amount as may be agreed upon between the Corporation and the Lead Agent (the "Offering").
